Monthly Archives: March 2022

The use of technology is inevitable in genetic testing given the increasing number of genetic tests and volume of data. OptraHEALTHs GeneFAXbrings better engagement, experience, and conversationality to genetics at unprecedented levels. Beilinson Hospital will conduct a research study for its patients undergoing genetic counseling and education, an important aspect for patients to make informed decisions. As part of this study, Beilinson Hospital will send GeneFAX virtual assistants to patients and assess the quality, time, and scale of genetic counseling sessions using GeneFAX.

On this occasion, Prof. Lina Basel Salmon (Head of Department, Genetics Institute) from Beilinson Hospital said, "Digital platforms assist in education of patients and help them to prepare for genetic counseling sessions. In addition, such tools facilitate the disclosure of testing results in a personalized and an understandable way."

GeneFAX is a unique solution that enables any patient to conversationally obtain information. Dr. Ashwin Kotwaliwale MD Ph.D., Medical Director, OptraHEALTH said, "GeneFAX is trusted by many large US labs, and we are excited to make GeneFAX available to our partners in Israel. GeneFAX empowers patients to make accurate health choices by providing a seamless experience."

Gamidor Diagnostics is supporting the pilot in the region as the adoption of genetic testing services powered by technology is gaining wider adoption. Amichai Cnaan of Gamidor Diagnostics said, "We are excited to evaluate advanced digital genetic counseling tools with OptraHEALTH and our customers for a better patient's treatment and accessibility to advanced preconception carrier screening and hereditary cancer testing."

About OptraHEALTH:

OptraHEALTH is focused on improving outcomes for consumers and leading Life Sciences and Healthcare organizations by utilizing our next-generation Artificial Intelligence Platform. OptraHEALTH's flagship product HealthFAX.ai Virtual Care Platform for Healthcare is used in healthcare for better engagement, experience, and education.

Media Inquiries Contacts:

Dr. Ashwin Kotwaliwale | Medical Director | OptraHEALTH | [emailprotected]

Amichai Cnaan | Business Unit Manager | Gamidor Diagnostics | [emailprotected]

SOURCE OptraHEALTH

View original post here:
OptraHEALTH and Beilinson Hospital (Clalit Health), Israel, announce GeneFAX Pilot for Genetic Counseling - PR Newswire

Precision medicine, genetic testing, antibiotic resistance, GMOs, cloning. Open almost any newspaper or click on any online news site, and youre likely to see headlines about many of these scientific topics. Woven through these stories is a common thread genetics.

But how much do readers really know about genetics? And how much does our knowledge or lack of it affect our opinions about these scientific issues and the stories that cover them? These are the questions students get to answer in a Summer Term course called Genetics 133 Genetics in the News.

Genetics is at the heart of many issues facing society, says course instructor Katie Vermillion Kalmon, who is director of undergraduate studies in the Department of Genetics. In Genetics 133, we gain a deeper understanding of the science behind the headlines so that the students can make informed decisions and help educate those around them.

Its a vital goal for students who run into genetics in so many corners of their lives, from the news to dinnertime discussions to ancestry testing kits. And in addition to the science, Vermillion Kalmon introduces the underlying ethics of these issues, an aspect that has been missing from many science classes.

We may be able to cure diseases, but should we? What if the genetics changes can be passed on to future generations? Who has access to the treatment? says Vermillion Kalmon, who received the 2021 Spitzer Excellence in Teaching Award. Social and ethical issues surround every topic, and the students need to think about these questions.

For many students, being able to take both the genetic information and the bioethics questions to other parts of their lives is one of the highlights of the class. I learned a lot of material and was able to talk to my family, coworkers, and friends about these types of topics. Everyone is interested, says Brenen Skalitzky, a first-year genetics and genomics student who took the course in summer 2021.

Genetics 133 is offered year-round but in different formats in-person during the semester and virtually over the summer. Vermillion Kalmon was able to fine-tune her online class, even before the pandemic hit, through help from Teach Online@UW (a campus learning community of instructors and instructional designers) and a UWMadison Continuing Studies grant.

Through the grant, an instructional designer showed her how to take her course from the classroom to the computer.

We knew as a department that online options were something we wanted to provide to students, so when Continuing Studies offered grants, we applied, says Vermillion Kalmon. The grant was greatly timed since I moved my course online prior to coronavirus. When the pandemic came, it was ready to go, and that allowed me to help train other faculty in my department to get ready for online teaching.

The summer online course is broken up into eight modules, each including lectures, news articles, group learning activities conducted via Zoom, and exams. The lectures and reading can be done on each students schedule, giving them flexibility during the summer when they may be working or studying in different time zones. And its a structure that has received universally positive feedback.

The class was taught incredibly well, says Alyssa Bhoopat, a first-year student who took the course in summer 2021. While there definitely was a lot of information to cover and take in, lecture videos were engaging, and the content was very interesting.

Skalitzky agreed, adding, I had lots of fun with the weekly team assignments. Hearing other students opinions about more controversial issues is eye-opening. I also wanted to be able to understand scientific journals and judge the reliability of news stories. Genetics 133 helped me with these skills, and the media-literacy component was very important to me.

The course is popular with non-genetics majors, Vermillion Kalmon says, but shes seeing more genetics majors enroll, especially through early-start programs. This includes both Bhoopat, a CALS QuickStart student, and Skalitzky, a participant in the Wisconsin Experience Summer Launch Program.

For Bhoopat, a genetics and genomics major, the advantages of taking the course early went beyond the class content. Being able to connect with faculty before starting the fall semester was invaluable, she explains. Dr. Vermillion Kalmon answered so many questions, even about topics outside the class, and she helped ease my nerves as the year started.

Vermillion Kalmon is happy to see more early-start students in her summer course. And although Genetics 133 isnt part of the curriculum for genetics and genomics majors, she would like to find more ways for those students to fit the class into their schedules and use it as a basis for their science courses to come. Students really learn a lot of genetics, and how much genetics relates to every aspect of our lives becomes very evident to them early on in the course, explains Vermillion Kalmon. It gives them an overview of the topics theyre going to see throughout their classes.

Continue reading here:
Into the heart of the science headlines with summer term course Genetics 133 CALS News - wisc.edu

SAN DIEGO, March 23, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr system and provider of NxClinical software, the leading solution for visualization, interpretation and reporting of genomic data, today announced that it is participating in-person at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. In addition to having six posters that present advances in clinical genetics research, Bionano will exhibit its complete portfolio of products and services as one company with more solutions.

The main ACMG conference sessions take place fromMarch 2326, 2022, in Nashville, TN with a virtual attendance option. As the first major genetics conference to be held in person in the U.S. since 2020, Bionanos commercial presence will reflect its expansion over the last two years, which now includes genome mapping solutions, software, and testing and laboratory services. Bionano acquired BioDiscovery in November 2021 and has integrated BioDiscoverys software products into its commercial offering while the combined software development teams focus on adding OGM data alongside sequencing and microarray data in NxClinical under the leadership of Dr. Soheil Shams, Bionanos Chief Informatics Officer and founder of BioDiscovery. Bionano acquired Lineagen in August 2020 and sells Lineagens menu of laboratory developed tests (LDTs) for pediatric neurodevelopmental disorders, including autism spectrum disorder. Bionano will have multiple attendees participating from both the scientific and commercial teams representing all product categories.

Bionano has evolved significantly in the last two years and we are now one team with more solutions that can benefit genetic clinicians and researchers. We believe our solutions can promote discovery by enabling geneticists to see more important genetic variations, and our testing services can play a role in ending the diagnostic odyssey for patients with genetic disorders. We are eager to showcase the ways in which we can partner with geneticists in our continued mission to transform how the world sees the genome, saidErik Holmlin, PhD, President and CEO ofBionano Genomics.

Scientific poster session contributions from Bionano and collaborators include:

Full content of the posters will be made available on the Bionano Genomics website once they have been presented at the conference.

About Bionano Genomics

Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Companys mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. For more information, visit bionanogenomics.com, lineagen.com or biodiscovery.com

Forward-Looking Statements of Bionano Genomics

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, plan, anticipate, estimate, intend and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the ability of our comprehensive solutions to benefit genetic clinician and researchers, including by promoting discovery and enabling geneticists to see important genetic variations; the ability of our testing services to play a role in providing diagnostic answers to patients with genetic disorders; and our ability to partner with geneticists in its continued mission to transform how the world sees the genome. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements in existing technologies; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support additional studies, adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2021 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on managements assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics, Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com

Investor Relations:Amy ConradJuniper Point+1 (858) 366-3243amy@juniper-point.com

See the article here:
Bionano Genomics Announces its Participation at the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting with Six...

Early data from landmark studyshows rapid whole genome sequencing (rWGS) provided diagnostic insights for more than half of newborns who received testing; one-third had no previously documented clinical suspicion of a genetic condition

GAITHERSBURG, Md., March 24, 2022 /PRNewswire/ -- GeneDx, LLC, a leader in genomic analysis, today announced new research in collaboration with the University of Washington, Seattle Children's and the Brotman-Baty Institute during the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting which demonstrates the utility of rapid whole genome sequencing (rWGS) to diagnose critically ill infants in the neonatal intensive care unit.

The data is part of SeqFirst, a study at the University of Washington examining the impact on care of broad access to routine whole genome sequencing in critically ill infants at Seattle Children's Hospital. Results showed that rapid whole genome sequencing provided a potential, partial or full diagnosis for 53% of newborns tested. Moreover, of those infants who received a diagnosis through whole genome sequencing, 30% had no previously-documented suspicion of a genetic condition, highlighting the limitations of strategies that rely on family history or clinical indicators to qualify for genetic testing. The impact of the genetic information was profound, leading to a change of management for 93% of these patients.

In addition to improving diagnosis, the SeqFirst data also suggested that making whole genome sequencing routine for critically ill patients in the NICU could help overcomes disparities in access to testing. Notably, 67% of patients in whom a genetic condition was not considered prior to testing identified as non-White.

"Our study shows how impactful routine use of whole genome sequencing can be in the neonatal ICU," said Mike Bamshad, M.D., SeqFirst principal investigator and professor and chief of genetic medicine in the department of pediatrics at the University of Washington and Seattle Children's Hospital. "Whole genome sequencing is the most advanced type of genetic testing and our study offers clear insight on the benefit of using it early in the diagnostic process to help families of children with health conditions find a precise genetic diagnosis, better anticipate their child's needs and take advantage of new treatments."

The SeqFirst study was established at the University of Washington with the goal of making whole genome sequencing more accessible. SeqFirst is one of several projects focused on access to testing in the NICU and for use in diagnosing developmental delays in outpatient settings.

"The data is clear rapid whole genome sequencing can provide critical diagnostic insights and much-needed answers for infants in the NICU," said Paul Kruszka, M.D., chief medical officer at GeneDx. "Whole genome sequencing is vastly underutilized in the NICU, despite the clear support for its utility in getting to a diagnosis quickly. Genetic disorders are a leading cause of morbidity and mortality in infants and very often every minute counts. Our hope is that by understanding the benefits of sequencing, we may be able to intervene earlier and pursue clinical approaches that improve outcomes."

GeneDx performs exome sequencing for infants enrolled in the SeqFirst study. GeneDx has played a pivotal role in pediatric disease diagnosis for hundreds of thousands of patients. With a database of more than 300,000 clinical exomes and corresponding clinical information, GeneDx is a key driver in understanding gene-disease relationships.

About GeneDx

GeneDx, LLC, is a global leader in genomics, providing testing to patients and their families worldwide. Originally founded by scientists from the National Institutes of Health, GeneDx offers a world-renowned clinical genomics program with particular expertise in rare and ultra-rare genetic disorders. In addition to its market-leading exome sequencing service, GeneDx offers a suite of additional genetic testing services, including diagnostic testing for hereditary cancers, cardiac, mitochondrial, neurological disorders, prenatal diagnostics, and targeted variant testing. To learn more, please visit http://www.genedx.com.

CONTACT:Julie McKeough,JMcKeough@genedx.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/new-research-illustrates-the-benefits-of-rapid-whole-genome-sequencing-for-critically-ill-infants-301509574.html

SOURCE GeneDx, Inc.

Here is the original post:
New Research Illustrates the Benefits of Rapid Whole Genome Sequencing for Critically Ill Infants - BioSpace

The globalreproductive genetics marketsize is expected to reach USD 11.23 Billion at a steady CAGR of 12.3% in 2028, according to latest analysis by Emergen Research.The report studies the factors influencing the growth of the industry in the global market and offers accurate predictions about the growth pattern. The report pays special attention to the key elements of the market, such as drivers, restraints, opportunities, threats, risks, limitations, and other aspects. The report covers a comprehensive analysis of the competitive landscape with a detailed analysis of the company profiles, product portfolio, and business expansion strategies.

Chromosomal abnormalities are responsible for 50% of miscarriages in first trimester. Reproductive genetics identifies embryos without these abnormalities so that they can be used for IVF, thus increasing the likelihood of healthy pregnancy and baby regardless of patient health. It also helps in achieving higher pregnancy rates per transfer, which reduces the need for IVF and results in low cost, time, and stress.

Advancements in genomic technologies and implementation of these technologies in clinical medicine has expanded their usage in diagnosis of genetic disorders, carrier screening, and identification of cause of infertility. Some tests are quite expensive, which deters couples from going ahead with the tests, but as there is a decline in cost of sequencing and surge in mixed-ethnicity population, an increasing number of couples/individuals are expected to opt for the procedure and this is expected to support market growth going ahead.

Get a Free sample of the report :https://www.emergenresearch.com/request-sample/695

In May 2021, Juno Diagnostics, Which is a company focusing on enhancing access to genetic health information, announced that closing of Series A financing round for USD 25 million led by Perceptive Xontogeny Venture (PXV) Fund. The fund will support product development, clinical validation studies, and commercial launch of JunoDxs product offerings for non-invasive prenatal testing.

Prenatal screening covers a variety of tests doctors recommend for a pregnant patient. Some prenatal screening tests determines the chances a baby may or may not have chromosomal disorders, such as Down Syndrome. Though recommended by doctors, it is non-invasive and optional, and poses no risk to pregnancy as it involves ultrasound and blood work.

Next Generation Sequencing (NGS) is a widely accepted genetic testing technology in the prenatal testing arena. NGS is able to detect embryos with unbalanced chromosomal translocations that were not identified earlier. NGS offers better coverage of the chromosomes, higher resolution, and is faster and more affordable.

Single gene disorders are among the most understood genetic disorders due to their inheritance patterns and relatively simple genetic causes. Some of the most common single gene disorders are sickle cell anaemia, hemochromatosis, cystic fibrosis, and Tay-Sachs. Reproductive genetic tests are done to detect the possibility of single gene disorders in babies.

Asia Pacific market revenue is expected to register a rapid CAGR during the forecast period due to increasing demand of genetic testing from India and China. In addition, increased utilization of IVF procedures and advancements in the healthcare sector are major factors driving growth of the market in the region.

Key players in the market include Illumina, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., Quest Diagnostics, Thermo Fisher Scientific Inc., Fulgent Genetics, Inc., Centogene AG, Myriad Genetics, Inc., Qiagen N.V., and OPKO Health, Inc

The report offers a comprehensive breakdown of the regional analysis of the market and subsequent country-wise analysis. The regional analysis of the market comprises of production volume information, consumption volume and patterns, revenue, and growth rate for the forecast period of 2020-2027. According to the regional analysis, the market is primarily spread over key geographical regions as follows:

North America(U.S., Canada)

Europe(U.K., Italy, Germany, France, Rest of EU)

Asia Pacific(India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America(Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa(Saudi Arabia, U.A.E., South Africa, Rest of MEA)

Request customization of the report:https://www.emergenresearch.com/request-for-customization/695

Competitive Terrain:

The GlobalReproductive GeneticsMarket is highly consolidated due to the presence of a large number of companies across this industry. The report discusses the current market standing of these companies, their past performances, demand and supply graph, production and consumption patterns, sales network, distribution channels, and growth opportunities in the market at length

Emergen Research has segmented the global reproductive genetics market on the basis of product type, procedure type, technology, application, and region:

Product Type Outlook (Revenue, USD Billion; 20182028)

Laboratory Developed Tests (LDT)

Kits

Reagents and Consumables

Procedure Type Outlook (Revenue, USD Billion; 20182028)

Pre-Natal Screening

Pre-Implantation Genetic Testing

Infertility Genetic Testing

Carrier Screening

Technology Outlook (Revenue, USD Billion; 20182028)

Next-Generation Sequencing (NGS)

Microarray

Polymerase chain reaction (PCR)

In-Situ Hybridization (ISH)

Application Outlook (Revenue, USD Billion; 20182028)

Single Gene Disorder

Aneuploidy

Structural Chromosomal Abnormality

Others

Reproductive GeneticsKey Coverage of report:

Reproductive GeneticsMarket share valuations of the segments on a country and global level.

Reproductive GeneticsMarket share analysis of the major market players.

Opportunities and growth prospects for the newReproductive Genetics7 market entrants.

Reproductive GeneticsMarket forecast for all the segments, sub-segments of the market.

Reproductive GeneticsMarket Trends (drivers, restraints, opportunities, challenges, threats, investment opportunities, and approvals)

Strategic endorsements in the key business segments on the basis ofReproductive Geneticsmarket valuations.

Competitive landscape mapping of the key development patterns.

Company profiling with detailed strategies, financial details, and recent developments.

Latest supply chain trends and technological advancements.

The report objectives are:

To evaluateReproductive Geneticsstatus, future forecast, growth opportunity, key market, and key players.

To present the GlobalReproductive Geneticsdevelopment in the different regions of the world.

To strategically study and segment the key players and comprehensively analyze their development plan and strategies.

To define, describe, and forecast the market by product type, market, and key regions.

Overview of theReproductive GeneticsMarket Report:

Introduction, Product Scope, Market Overview, and Opportunities

Analysis of the Manufacturers with sales, revenue, and price analysis

Comprehensive analysis of the competitive landscape

Extensive profiling of the key competitors along with their business strategies and market size

Regional analysis of the market along with sales, revenue, market share, and global position

Country-wise analysis of the market along with types, applications, and manufacturing

Strategic recommendations to established players as well as new entrants

In-depth analysis of the risks, restraints, and limitations in theReproductive Geneticsindustry

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Read More:https://www.emergenresearch.com/industry-report/reproductive-genetics-market

Related Reports:

Patient Engagement Solutions Market:https://www.emergenresearch.com/industry-report/patient-engagement-solutions-market

Nucleic Acid Isolation and Purification Market:https://www.emergenresearch.com/industry-report/nucleic-acid-isolation-and-purification-market

Non-Invasive Prenatal Testing Market: https://www.emergenresearch.com/industry-report/non-invasive-prenatal-testing-market

RNA Transcriptomics Market: https://www.emergenresearch.com/industry-report/in-vitro-fertilization-market

Blockchain in Healthcare:https://www.forbes.com/sites/forbestechcouncil/2021/12/07/four-key-medtech-software-development-trends-for-2022/?sh=23e843f420d5

About Us:At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web:www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail:[emailprotected]

Facebook|LinkdIn|Twitter|Blogs

The post Reproductive Genetics Market Size by 2027 | Industry Segmentation by Type, Key News and Top Companies Profiles appeared first on Market O Graphics.

Continued here:
Reproductive Genetics Market Size by 2027 | Industry Segmentation by Type, Key News and Top Companies Profiles - Digital Journal

ANN ARBOR, Mich. (WOOD) A new study led by researchers at the University of Michigan shows how genetics play a key role in how each persons body reacts to booster shots.

The study was a partnership with the Australian National Health and Research Center and the American Foundation for AIDS Research. Unlike the original vaccine, boosters re-expose the immune system to a virus or some portion of it to boost the bodys natural immune response. Not every body reacts the same way. The booster doses increase the number of antibodies in a persons system, but genetics dictate how well the immune receptors stick to those antibodies.

Different people vary in the amount and type of antibodies they produce, Kelly Arnold wrote in a 2021 study published in Cell Reports Medicine.

Arnold is an assistant professor of biomedical engineering at the University of Michigan and one of the leading researchers on the study.

Depending on their genetics, they also have different protein sequences in their antibodies and immune cell receptors that cause them to bind differently, Arnold said.

She says two people can have the same antibody count but have different immune responses and, theoretically, booster doses can be specifically designed to make them more effective for people depending on their genetic makeup.

That technology is not yet available, but it could be possible.

Depending on your genetic background, weve found that vaccine boosting may be more or less effective in activating certain innate immune functions, Arnold told the University of Michigan Health Lab. And in some people, where boosting the concentrations of antibodies was ineffective, being able to change the affinity of antibodies could be the more successful route.

Arnold and her research team have worked with their partners in Australia, Thailand and other places in the United States to create a computer model to determine how different genetic factors dictate immune responses.

Melissa Lemke, a Ph.D. candidate who led the 2021 study, says vaccine formulas developed for specific genetic traits is key in fighting viruses that mutate rapidly, like COVID-19, HIV or influenza.

This means that in order to protect all people to the same degree from a variety of viral mutations, we need an array of possible solutions that can be matched to any given persons health status, sex, age and genetic background, Lemke told the University of Michigan Health Lab. Computational tools like this one are going to be essential in speeding up the search for mechanisms that can be implemented to create effective vaccines for all.

Here is the original post:
Study: Genetic makeup plays key role in effectiveness of booster doses - WOODTV.com

FACULTY OF NATURAL AND AGRICULTURAL SCIENCESDEPARTMENT OF BIOCHEMISTRY, GENETICS AND MICROBIOLOGYGENETICSLECTURER (BIOINFORMATICS)

In pursuit of the ideals of excellence and diversity, the University of Pretoria wishes to invite applications for the above vacancy.

The University of Pretoria's commitment to quality makes us one of the top research Universities in the country and gives us a competitive advantage in international science and technology development.

BACKGROUND:

The incumbent is expected to be positioned in the Centre of Bioinformatics and Computational Biology, which resides within the Department of Biochemistry, Genetics and Microbiology, to provide ongoing bioinformatics services and support, which includes the development of bioinformatics tools and resources for both internal and public use. The incumbent will also have an academic mandate to teach at undergraduate and postgraduate levels in Bioinformatics and Genetics, as well as a research mandate to build an active research programme which will enhance the Departments research profile and grow capacity in postgraduate supervision.

RESPONSIBILITIES:

The incumbent will actively participate in the following areas:

MINIMUM REQUIREMENTS:

REQUIRED COMPETENCIES (SKILLS, KNOWLEDGE AND BEHAVIOURAL ATTRIBUTES):

ADDED ADVANTAGES AND PREFERENCES:

PLEASE NOTE: The Department of Biochemistry, Genetics and Microbiology (BGM) reserves the right to request and review copies of academic publications (papers/dissertation/ thesis) for suitability before a candidate is shortlisted. All shortlisted applicants will be expected to present a lecture on a given topic within the Department.

The annual remuneration package will be commensurate with the incumbents level of appointment, as determined by UP policy guidelines. UP subscribes to the BESTMED and UMVUZO medical aid schemes and contributes 50% of the applicable monthly premium.

Applicants are requested to apply online at http://www.up.ac.za, and follow the link: Careers@UP.

In applying for these posts, please attach:

CLOSING DATE: 7 April 2022

No application will be considered after the closing date, or if it does not comply with at least the minimum requirements.

ENQUIRIES:

Mrs S Mahlangu, Email: shado.mahlangu@up.ac.za for application-related and Prof F Joubert, fourie.joubert@up.ac.za for post content enquiries.

Should you not hear from the University of Pretoria by 31 May 2022, please accept that your application has been unsuccessful.

The University of Pretoria is committed to equality, employment equity and diversity.

In accordance with the Employment Equity Plan of the University and its Employment Equity goals and targets, preference may be given, but is not limited to candidates from under-represented designated groups.

All candidates who comply with the requirements for appointment are invited to apply. All candidates agree to undergo verification of personal credentials.

The University of Pretoria reserves the right to not fill the advertised positions.

The rest is here:
Lecturer, Bioinformatics, Department of Biochemistry job with UNIVERSITY OF PRETORIA | 287312 - Times Higher Education